- Home
- TONX vs ZNTL Comparison
TONX vs ZNTL Comparison
Compare TONX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TONX | ZNTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5M | 156.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TONX | ZNTL |
|---|---|---|
| Price | $1.93 | $2.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 400.0K | ★ 614.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | $526.82 | N/A |
| Revenue Next Year | $45.45 | N/A |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $1.01 |
| 52 Week High | $8.23 | $3.95 |
Technical Indicators
Market Signals| Indicator | TONX | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 46.91 |
| Support Level | $1.83 | $1.27 |
| Resistance Level | $3.18 | $2.69 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 45.83 | 32.29 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.